MA31079B1 - Sel de potassium cristallin d'analogues de la lipoxine a4 - Google Patents

Sel de potassium cristallin d'analogues de la lipoxine a4

Info

Publication number
MA31079B1
MA31079B1 MA32056A MA32056A MA31079B1 MA 31079 B1 MA31079 B1 MA 31079B1 MA 32056 A MA32056 A MA 32056A MA 32056 A MA32056 A MA 32056A MA 31079 B1 MA31079 B1 MA 31079B1
Authority
MA
Morocco
Prior art keywords
crystalline potassium
potassium salt
lipoxine
analogs
crystalline
Prior art date
Application number
MA32056A
Other languages
English (en)
French (fr)
Inventor
Tilo Haag
Danja Grossbach
Gabriele Winter
Michael Sander
Wolfgang Beckmann
Klaus Bartel
Christian Dinter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31079(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31079B1 publication Critical patent/MA31079B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
MA32056A 2006-12-04 2009-06-29 Sel de potassium cristallin d'analogues de la lipoxine a4 MA31079B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
MA31079B1 true MA31079B1 (fr) 2010-01-04

Family

ID=39076610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32056A MA31079B1 (fr) 2006-12-04 2009-06-29 Sel de potassium cristallin d'analogues de la lipoxine a4

Country Status (28)

Country Link
US (2) US7906678B2 (https=)
EP (2) EP3489214A1 (https=)
JP (1) JP5410984B2 (https=)
KR (3) KR20090101169A (https=)
CN (1) CN101553456B (https=)
AR (1) AR064116A1 (https=)
AU (1) AU2007327765B2 (https=)
BR (1) BRPI0719679A2 (https=)
CA (1) CA2670791C (https=)
CL (1) CL2007003468A1 (https=)
CO (1) CO6190608A2 (https=)
CR (1) CR10837A (https=)
DO (1) DOP2009000130A (https=)
EA (1) EA018615B1 (https=)
EC (1) ECSP099380A (https=)
IL (1) IL198434A (https=)
MA (1) MA31079B1 (https=)
MX (1) MX2009005911A (https=)
MY (1) MY147951A (https=)
NO (1) NO20092528L (https=)
NZ (1) NZ577338A (https=)
PE (2) PE20120395A1 (https=)
SV (1) SV2009003286A (https=)
TN (1) TN2009000167A1 (https=)
TW (1) TWI415833B (https=)
UY (1) UY30755A1 (https=)
WO (1) WO2008068041A1 (https=)
ZA (1) ZA200904689B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
EP2958560B1 (en) * 2013-02-21 2019-05-08 Forsyth Dental Infirmary for Children Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
EP3270693B1 (en) * 2015-03-18 2021-06-30 Forsyth Dental Infirmary for Children Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
ES2827796T3 (es) * 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JPH08512023A (ja) 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
CA2675416A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
ES2249257T3 (es) 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
ES2215752T3 (es) 1999-11-09 2004-10-16 Alcon, Inc Lipoxina a4 y analogos para el tratamiento del ojo seco.
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
AU2002347539A1 (en) 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
JP4634716B2 (ja) 2002-03-15 2011-02-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
SI1589966T1 (sl) 2003-01-30 2011-06-30 Lek Pharmaceuticals D.D. Postopek čiščenja losartana
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
WO2007053724A2 (en) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Crystalline forms of cefdinir potassium salt
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4

Also Published As

Publication number Publication date
WO2008068041A1 (en) 2008-06-12
NZ577338A (en) 2011-02-25
UY30755A1 (es) 2008-07-31
EA018615B1 (ru) 2013-09-30
DOP2009000130A (es) 2009-08-15
CN101553456A (zh) 2009-10-07
CA2670791C (en) 2017-01-03
IL198434A (en) 2012-09-24
TWI415833B (zh) 2013-11-21
EP2089350B1 (en) 2018-08-22
MY147951A (en) 2013-02-15
PE20120395A1 (es) 2012-05-23
IL198434A0 (en) 2010-02-17
EP3489214A1 (en) 2019-05-29
AU2007327765B2 (en) 2012-04-12
US7906678B2 (en) 2011-03-15
CA2670791A1 (en) 2008-06-12
CN101553456B (zh) 2013-08-28
KR20090101169A (ko) 2009-09-24
KR20140135847A (ko) 2014-11-26
CO6190608A2 (es) 2010-08-19
MX2009005911A (es) 2009-09-07
ZA200904689B (en) 2011-10-26
TN2009000167A1 (en) 2010-10-18
NO20092528L (no) 2009-08-26
JP5410984B2 (ja) 2014-02-05
JP2010511649A (ja) 2010-04-15
BRPI0719679A2 (pt) 2014-01-14
EA200900732A1 (ru) 2009-12-30
HK1135961A1 (en) 2010-06-18
US20080182897A1 (en) 2008-07-31
CR10837A (es) 2009-07-23
SV2009003286A (es) 2009-10-02
US8049035B2 (en) 2011-11-01
PE20081200A1 (es) 2008-11-06
US20110124910A1 (en) 2011-05-26
AR064116A1 (es) 2009-03-11
EP2089350A1 (en) 2009-08-19
CL2007003468A1 (es) 2008-07-04
AU2007327765A1 (en) 2008-06-12
TW200838847A (en) 2008-10-01
ECSP099380A (es) 2009-11-30
KR20160054030A (ko) 2016-05-13

Similar Documents

Publication Publication Date Title
MA31079B1 (fr) Sel de potassium cristallin d'analogues de la lipoxine a4
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA32965B1 (fr) Derives de sulfonamides
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
NO20075453L (no) Sammensetning inneholdende antidemensmiddel
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA35833B1 (fr) Dérivés de bétuline
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA34760B1 (fr) Composés et leurs utilisation